3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Classical hematology
1
CNS
1
Conditions
Urinary Tract Infections
1
Staphylococcal Infections
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Sepsis
1
Seizures
1
Schizophrenia, Treatment-Resistant
1
Schizophrenia
1
Retinitis
1
Renal Insufficiency, Chronic
1
Pulmonary Arterial Hypertension
1
Pneumonia
1
Pain
1
Neutropenia
1
Migraine Disorders
1
Menorrhagia
1
Meningitis, Bacterial
1
Meningitis
1
Intraabdominal Infections
1
Influenza, Human
1
Inflammation
1
Infections
1
Hypokalemia
1
Hypertension
1
Hyperaldosteronism
1
Herpes Simplex
1
Hemophilia A
1
Hemangioma, Capillary
1
Heart Failure
1
Heart Arrest
1
Interventions
Voriconazole
4
Vancomycin
3
Fluconazole
3
Filgrastim
3
Ciprofloxacin
3
Caspofungin
3
liposomal amphotericin B
2
Trimethoprim, Sulfamethoxazole Drug Combination
2
Therapeutics
2
Piperacillin, Tazobactam Drug Combination
2
Peripheral Blood Stem Cell Transplantation
2
Melphalan
2
Itraconazole
2
Granulocyte Colony-Stimulating Factor
2
Fosfomycin
2
Daptomycin
2
Cyclophosphamide
2
Cefazolin
2
Antibiotic Prophylaxis
2
ziprasidone
1
threonic acid
1
telavancin
1
soybean oil, phospholipid emulsion
1
plerixafor
1
monalizumab
1
lime
1
human papillomavirus vaccine, L1 type 16, 18
1
fluorescein isothiocyanate-keyhole limpet hemocyanin
1
fludarabine phosphate
1
fish oil triglycerides
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Infections
×
Lurasidone Hydrochloride
×
Clear all
NCT01431326
2023-09-06
PTN_POPS
Duke University
Completed
3,520 enrolled